window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : March 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

checkpoint inhibitors

  • Clinical Development,Clinical Trials,Immunology,Oncology,Pharmaceuticals and therapeutics

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    January 26, 2026
  • Artificial Intelligence,Oncology,Precision medicine

    Biostate AI expands RNA-based precision medicine with new partnerships across China, India and the US

    Global collaborations boost dataset powering AI diagnostics for cancer, cardiovascular [...]

    July 24, 2025
  • Biologics & Biosimilars,Drug Development,Oncology,Research & Development

    Why immunotherapy sometimes fails: Study reveals unintended effects of antibody design

    A new study from researchers in Japan has uncovered a [...]

    July 24, 2025
  • Clinical Trials,Drug Development,Oncology,Precision medicine,Research & Development

    Scancell’s iSCIB1+ shows 69% response rate in advanced melanoma in Phase 2 study

    Scancell has reported updated results from its Phase 2 SCOPE [...]

    July 22, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ViiV Healthcare reports 12-month data showing lotivibart maintains viral suppression in ultra long-acting HIV regimen
    Categories: Clinical Development, Infectious Diseases, Patient Centricity, Precision medicine
  • SPT Labtech and Illumina to develop automated platform for decentralised oncology genomics
    Categories: Diagnostics, Oncology, Partnerships & Funding
  • Young adults in US, UK and Australia hit hardest by global mental health decline
    Categories: Clinical studies, Digital Health, Global health, Mental health, Neurosciences
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top